Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK ( TheStreet) -- One day we'll get to talk about stocks again, Jim Cramer told his "Mad Money" TV show viewers Friday, but unfortunately that day will not be today as Washington continues to dominate the financial headlines. That's why Cramer said his game plan for next week's trading is identical to this week's: sell first and ask questions later. Other than the continued hardline discussions in Washington, Cramer said the only number that will move the markets will be Friday's jobs report. Here again, it's a "good news is bad news" situation as putting more people back to work will be seen as the time Ben Bernanke will drop the boom on interest rates. Outside of Washington, Cramer said he'll be watching Paychex ( PAYX) on Monday, as he worries that prior gains may be given up by a weaker outlook. Tuesday's only stock news will be Walgreens ( WAG), Cramer said, and that company has been on a roll, reclaiming lost market share. Wednesday brings more comments from Bernanke, which may help to soothe fears for Friday, Cramer noted. Also on Wednesday, seed giant Monsanto ( MON) reports. Cramer said that while Monsanto should do well with a growing global economy, the issue of farm subsidies could come up in Washington, making even this stock a tough one to call. Also on the watch list are two high-yielders, Clorox ( CLX) and Eli Lilly ( LLY). Cramer said both these stocks could also come under fire depending on what Bernanke & Company have to say. Cramer said his advice is to continue to raise cash and wait for the moment a budget deal is reach, because even a bad deal will give the market certainty and only then will it be allowed to head higher.
No Huddle offenseIn his "No Huddle Offense" segment, Cramer explained what he means by a great "regional to national" story. He said in the case of Dunkin Brands ( DNKN), a chain that's clustered in the Northeast and along the East Coast, there is still many years of growth ahead as this high quality operator adds locations in the two-thirds of the country where it has none.
Compare that opportunity to that of J.C. Penney ( JCP) or Sears Holdings ( SHLD), retailers that already have locations throughout the entire country. Those chains need fewer, not more, stores, said Cramer, the complete opposite of Dunkin, which could easily support thousands more. So the next time Cramer talks about "regional to national," just think about Dunkin Brands and the decade of growth it has in front it.
Speculation FridayFor "Speculation Friday," Cramer turned his sights on Pharmacyclics ( PCYC), the small biotech firm that received not one, but three analyst upgrades despite the stock having already soared 130% so far this year. Cramer said that he doesn't care where the stock of Pharmacyclics came from, only where it's going, and in this case he completely agrees with the three analysts. Why? Because Pharmacyclics' new blood cancer drug, submitted for Food and Drug Administration approval this summer, is proving to be a blockbuster therapy that could revolutionize how blood cancers are treated. Cramer noted that what's exciting about Pharmacyclics is not that its drug is showing remarkable results with few side effects, but that the drug is achieving these results all by itself. This new drug is so good, it turns out, it doesn't need to be part of a cocktail of drugs as all other therapies dictate. Given the hefty price tag of the drug, $125,000 a year, analysts are now expecting $6.5 billion a year in peak revenue. Not all of that will reach Pharmacyclics, however, as it has a 50/50 split with Johnson & Johnson ( JNJ). While some analyst shy away from Pharmacyclics given its $10 billion valuation, Cramer noted that companies including Alexion Pharmaceuticals ( ALXN), are also expected to bring in $3.5 billion, and that company is valued at $22 billion -- meaning Pharmacyclics could double or more and still be valued in line with its peers. There are still risks, however, which is why investors need to do their homework before investing, Cramer noted,.
Lightning RoundIn the Lightning Round, Cramer was bullish on LifeLock ( LOCK), Oasis Petroleum ( OAS), Rite Aid ( RAD) and Verizon ( VZ).
Cramer was bearish on Linn Energy ( LINE).